2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
Acute Coronary Syndrome
/ diagnosis
Anticoagulants
/ adverse effects
Atrial Fibrillation
/ diagnosis
Cardiac Catheterization
/ adverse effects
Consensus
Fibrinolytic Agents
/ adverse effects
Heart Valve Diseases
/ diagnosis
Hemorrhage
/ chemically induced
Humans
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation Inhibitors
/ adverse effects
Risk Assessment
Risk Factors
Stroke
/ diagnosis
Treatment Outcome
Journal
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
25
06
2018
accepted:
28
06
2018
pubmed:
28
7
2018
medline:
8
9
2020
entrez:
28
7
2018
Statut:
ppublish
Résumé
In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.
Identifiants
pubmed: 30052888
pii: 5056658
doi: 10.1093/europace/euy174
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Platelet Aggregation Inhibitors
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
192-193Investigateurs
Tatjana Potpara
(T)
Carina Blomström Lundqvist
(C)
Harry Crijns
(H)
Jan Steffel
(J)
Hein Heidbüchel
(H)
Goran Stankovic
(G)
Juhani Airaksinen
(J)
Jurrien M Ten Berg
(JM)
Davide Capodanno
(D)
Stefan James
(S)
Hector Bueno
(H)
Joao Morais
(J)
Dirk Sibbing
(D)
Bianca Rocca
(B)
Ming-Hsiung Hsieh
(MH)
Nazem Akoum
(N)
Deborah J Lockwood
(DJ)
Jorge Rafael Gomez Flores
(JR)
Ronald Jardine
(R)